Sponsored Links
| N30 Pharma Announces FDA Approval To Initiate Phase 1 Clinical Trial For First-in-Class Drug |
 |
 |
 |
| Medical News - Irritable-Bowel Syndrome | |||
|
N30 Pharmaceuticals, LLC announced the approval of its Investigational New Drug Application for N6022 by the U.S. Food and Drug Administration. N6022, a first-in-class inhibitor of s-nitrosoglutathione reductase (GSNOR), has the potential to be an important new treatment for acute exacerbations of asthma, chronic obstructive pulmonary disease (COPD) and inflammatory bowel disease (IBD)... Read more: Irritable-Bowel Syndrome News From Medical News Today
|